LEIDEN, Netherlands, May 23 /PRNewswire/ -- Crucell N.V. (Nasdaq: CRXL - news; Euronext Amsterdam: CRXL) today announced that it has developed and tested a new, improved and large r phage antibody-display library of human antibody fragments, for target discovery and the development of antibody based therapeutics.
This library is part of Crucell's MAbstract(TM) technology to discover novel targets on disease-associated cells and generate fully human monoclonal antibodies against those targets in the areas of cancer, chronic inflammation, and cardiovascular disease. The library is employed to search for novel targets that are specifically present on disease-associated cells using a proprietary subtraction method of selection. The new library extends the versatility of the selection procedures for therapeutic human antibodies, and now contains around 50 billion different antibody fragments, which makes it one of the most comprehensive phage antibody-display libraries in existence.
``We are proud to have developed this new library, that includes features that will further enhance and accelerate our MAbstract(TM) program for the identification of novel targets and hence the development of biopharmaceuticals,'' says Dr. Ton Logtenberg, Chief Scientific Officer of Crucell. ``Compared to 4 previous libraries that we have constructed, this new library is not only improved in its capacity to identify new targets, it also contains ten times more human antibody fragments.'' |
